Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A
ESMO-MCBS v1.1
Scorecard version: 1

Indication details

Tumour Type
Gastrointestinal Cancers
Tumour Sub-type
Pancreatic cancer
Tumour stage
Early
Combined Agent(s)
Capecitabine
Control Arm
Gemcitabine
Treatment Setting
Resected pancreatic ductal adenocarcinoma
Trial Name
ESPAC-4

Primary Outcome(s)

Primary Outcome(s)
OS
Form(s)
Form 1

Outcome Data

OS Control
25.5 months
OS Gain
2.5 months >10% at five years
OS HR
0.82 (0.68-0.98)

Final Score (after adjustments)

Final curative score
A
Release date
15.05.2019

DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.